Schering, AG

MS-325 for magnetic resonance angiography submitted for approval in the U.S.

Published in Law and Health Weekly, January 12th, 2004

Schering, AG, Germany, (SCH) announced that MS-325, its new contrast agent for magnetic resonance angiography (MRA), has been submitted for marketing approval in the United States by its development partner, EPIX Medical, Inc., (EPIX).

MS-325 is, according to the company, the first magnetic resonance blood pool contrast agent which has successfully completed clinical development for vascular imaging.

"MS-325 offers a real breakthrough in the field of vascular imaging. It is an innovative MRA contrast agent for the detection of structural abnormalities, such as stenosis and aneurysm, in patients with known or suspected vascular disease," said Michael...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2004-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry